研發管綫

攀上疾病早期攔截的新高度

MiRXES 2021 在研產品

解決整個連貫醫療過程中臨床未填補的需求

癌症早期攔截研發綫路

癌症早期檢測

依據RNA 的多種癌症多組學篩查檢測。

+ 胃癌篩查試驗最先推出。

+ 肺癌篩查試驗將於 2021 年年底啟動。

+ 隨後推出結直腸癌、肝癌、乳腺癌、胰腺癌和卵巢癌檢測。

精準腫瘤學

癌症治療指導和耐藥性預測的快速回交檢測服務。

+ 推出 4 天回交的 APEX 組織和液體活檢檢測服務。

+ 隨後推出全面的基因組分析、免疫治療、血液腫瘤學和體細胞突變檢測。

疾病早期檢測綫路

非腫瘤學診斷

感染性、心血管和代謝性疾病的多組學早期檢測和伴隨診斷檢測。

+ Fortitude COVID-19 RT-PCR 測試和大流行支持,提供一整套測試解決方案。
+ 依次介紹肺動脈高壓、心力衰竭和胰島素抵抗的測試。

癌症早期攔截研發綫路

癌症早期檢測

依據RNA 的多種癌症多組學篩查檢測。

+ 胃癌篩查試驗最先推出。

+ 肺癌篩查試驗將於 2021 年年底啟動。

+ 隨後推出結直腸癌、肝癌、乳腺癌、胰腺癌和卵巢癌檢測。

精準腫瘤學

癌症治療指導和耐藥性預測的快速回交檢測服務。

+ 推出 4 天回交的 APEX 組織和液體活檢檢測服務。

+ 隨後推出全面的基因組分析、免疫治療、血液腫瘤學和體細胞突變檢測。

疾病早期檢測綫路

非腫瘤學診斷

• 感染性、心血管和代謝性疾病的多組學早期檢測和伴隨診斷檢測。

+ 胃癌篩查試驗將最先推出。

+ 肺癌篩查試驗將於 2021 年年底啟動。

The continuum of care:

點擊此處,閱讀關於我們的最新動態和關鍵科學論文。

24 Mar 2021

Mammography is extensively used for breast cancer screening but has high false-positive rates. This paper describes the discovery, development, and validation of a serum 6-miRNA panel to discriminate between malignant and benign breast lesions among women with abnormal mammograms.

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

版權所有©2021 MiRXES Pte Ltd. 保留所有權利。| 私隱政策
Scroll to Top